ArticleFrontiers in oncology2021
CXCL12 and CD3E as Indicators for Tumor Microenvironment Modulation in Bladder Cancer and Their Correlations With Immune Infiltration and Molecular Subtypes.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 22 citations in OpenAlex.
- B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- The Prognostic Value and Immunotherapeutic Characteristics of GFPT2 in Pan-cancer.Combinatorial chemistry & high throughput screening · 2025Article
- The Laws of Attraction: Chemokines as Critical Mediators in Cancer Progression and Immunotherapy Response in Bladder Cancer.Cancers · 2024Review
- Gene expression profiles associated with early relapse during first remission induction in canine multicentric high-grade B-cell lymphoma.The Journal of veterinary medical science · 2024Article
- Integrated Bioinformatics Analysis for Revealing CBL is a Potential Diagnosing Biomarker and Related Immune Infiltration in Parkinson's Disease.International journal of general medicine · 2024Article
- Article
- Identification and validation of 5-methylcytosine-associated genes in diffuse large B-cell lymphoma.Heliyon · 2023Article
- Identification of prognostic hub genes and therapeutic targets for selenium deficiency in chicks model through transcriptome profiling.Scientific reports · 2023Article
- Radiotherapy-Related Gene Signature in Prostate Cancer.Cancers · 2022Article
- The Urinary Microbiome: Role in Bladder Cancer and Treatment.Diagnostics (Basel, Switzerland) · 2022Review
- Article
- Comprehensive analysis of prognostic value and immune infiltration of CXC chemokines in pancreatic cancer.BMC medical genomics · 2022Article
- Gene expression profiling reveals candidate biomarkers and probable molecular mechanisms in chronic stress.Bioengineered · 2022Article
- An Analysis of BMP1 Associated with m6A Modification and Immune Infiltration in Pancancer.Disease markers · 2022Article
- Comprehensive Exploration of Tumor Microenvironment Modulation Based on the ESTIMATE Algorithm in Bladder Urothelial Carcinoma Microenvironment.Frontiers in oncology · 2022Article
- Dietary supplementation ellagic acid on the growth, intestinal immune response, microbiota, and inflammation in weaned piglets.Frontiers in veterinary science · 2022Article
- An EMT-based risk score thoroughly predicts the clinical prognosis, tumor immune microenvironment and molecular subtypes of bladder cancer.Frontiers in immunology · 2022Article
- Tumor microenvironment and epithelial-mesenchymal transition in bladder cancer: Cytokines in the game?Frontiers in molecular biosciences · 2022Review
- Solute carrier family 12 member 8 (SLC12A8) is a potential biomarker and related to tumor immune cell infiltration in bladder cancer.Bioengineered · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer (BLCA) represents the ninth most common malignant tumor in the world and is characterized by high recurrence risk. Tumor microenvironment (TME) plays an important role in regulating the progression of BLCA. Immunotherapy, including Bacillus Calmette-Guerin (BCG) and programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1), is closely associated with TME and is widely used for treating BLCA. But parts of BLCA patients have no response to these treatment ways, thus a better understanding of the complex TME of BLCA is still needed. We downloaded the gene expression profile and corresponding clinical information of 414 BLCA patients from the TCGA database.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.